A 12-month, monthly repeat-dose Phase II CFTR non-viral (liposome) gene-transfer clinical trial showed significant, albeit modest and transient, lung function benefits in CF patients (Alton et al., 2015). Here, CFTR is linked to cystic fibrosis.